Compare Dr. Reddys with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 34.3 28.5 120.7% View Chart
P/BV x 4.7 4.0 116.9% View Chart
Dividend Yield % 0.6 0.5 111.1%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
CIPLA
Mar-20
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs3,363586 574.4%   
Low Rs2,352357 659.2%   
Sales per share (Unadj.) Rs1,054.2207.0 509.2%  
Earnings per share (Unadj.) Rs121.918.6 655.6%  
Cash flow per share (Unadj.) Rs190.233.2 573.6%  
Dividends per share (Unadj.) Rs25.004.00 625.0%  
Dividend yield (eoy) %0.90.8 103.1%  
Book value per share (Unadj.) Rs938.7195.5 480.2%  
Shares outstanding (eoy) m166.17806.35 20.6%   
Bonus/Rights/Conversions ESOPESOS-  
Price / Sales ratio x2.72.3 119.1%   
Avg P/E ratio x23.425.3 92.5%  
P/CF ratio (eoy) x15.014.2 105.7%  
Price / Book Value ratio x3.02.4 126.3%  
Dividend payout %20.521.5 95.3%   
Avg Mkt Cap Rs m474,831379,912 125.0%   
No. of employees `00021.725.8 83.8%   
Total wages/salary Rs m33,80230,270 111.7%   
Avg. sales/employee Rs Th8,091.06,459.6 125.3%   
Avg. wages/employee Rs Th1,561.31,171.2 133.3%   
Avg. net profit/employee Rs Th935.8580.2 161.3%   
INCOME DATA
Net Sales Rs m175,170166,949 104.9%  
Other income Rs m6,2063,442 180.3%   
Total revenues Rs m181,376170,391 106.4%   
Gross profit Rs m24,42132,060 76.2%  
Depreciation Rs m11,34811,747 96.6%   
Interest Rs m9831,974 49.8%   
Profit before tax Rs m18,29621,782 84.0%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,4036,312 -22.2%   
Profit after tax Rs m20,26014,995 135.1%  
Gross profit margin %13.919.2 72.6%  
Effective tax rate %-7.729.0 -26.5%   
Net profit margin %11.69.0 128.8%  
BALANCE SHEET DATA
Current assets Rs m125,991117,038 107.6%   
Current liabilities Rs m72,14143,931 164.2%   
Net working cap to sales %30.743.8 70.2%  
Current ratio x1.72.7 65.6%  
Inventory Days Days7396 76.3%  
Debtors Days Days10585 123.1%  
Net fixed assets Rs m83,854107,424 78.1%   
Share capital Rs m8311,613 51.5%   
"Free" reserves Rs m155,157156,018 99.4%   
Net worth Rs m155,988157,630 99.0%   
Long term debt Rs m1,30423,693 5.5%   
Total assets Rs m232,253236,626 98.2%  
Interest coverage x19.612.0 162.9%   
Debt to equity ratio x00.2 5.6%  
Sales to assets ratio x0.80.7 106.9%   
Return on assets %9.17.2 127.5%  
Return on equity %13.09.5 136.5%  
Return on capital %12.612.8 98.2%  
Exports to sales %033.0 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,175 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,19356,036 150.2%   
Fx outflow Rs m39,6166,764 585.7%   
Net fx Rs m44,57749,272 90.5%   
CASH FLOW
From Operations Rs m29,84130,685 97.3%  
From Investments Rs m-4,9231,040 -473.2%  
From Financial Activity Rs m-25,159-29,488 85.3%  
Net Cashflow Rs m-2662,340 -11.4%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 26, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - CADILA HEALTHCARE COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS